Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | THPO | P40225 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | HPGD | P15428 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383649 | 1.00 | HTR2A (0.46) | HTR2ACYP3A4MEN1KMT2ACYP2D6 | |
| Bromide SCHEMBL3668719 | 0.99 | HTR2A (0.45) | HTR2ACYP3A4MEN1KMT2ACYP2D6 | |
| SCHEMBL22952971 | 0.84 | HTR2A (0.35) | HTR2ACYP3A4MEN1KMT2ACYP2D6 | |
| SCHEMBL22953341 | 0.78 | PARP1 (0.43) | CYP3A4MEN1KMT2ACYP2D6PARP1 | |
| SCHEMBL6391686 | 0.77 | HTR2A (0.60) | HTR2ACYP3A4MEN1KMT2ACYP2D6 | |
| SCHEMBL3680945 | 0.75 | HTR2A (0.42) | HTR2ACYP3A4MEN1KMT2ACYP2D6 | |
| SCHEMBL22952976 | 0.74 | HTR2A (0.33) | HTR2ACYP3A4MEN1KMT2ACYP2D6 | |
| SCHEMBL16938669 | 0.74 | HTR2A (0.60) | HTR2ACYP3A4MEN1KMT2ACYP2D6 | |
| SCHEMBL29383346 | 0.74 | HTR2A (0.60) | HTR2ACYP3A4MEN1KMT2ACYP2D6 | |
| SCHEMBL3672464 | 0.74 | HTR2A (0.60) | HTR2ACYP3A4MEN1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050232870-A1 | Method of treatment of dopamine-related dysfunction | PURDUE RESEARCH FOUNDATION AND UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2005-10-20 | — | — | US | disclosed |
| US-6916823-B2 | Method of treatment of dopamine-related dysfunction | PURDUE RESEARCH FOUNDATION (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050080266-A1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-04-14 | — | — | US | disclosed |
| US-6413977-B1 | D1 AGONISTS; CENTRAL AND PERIPHERAL NERVOUS SYSTEM DYSFUNCTIONS; IMPROVING COGNITION AND MEMORY; PARKINSON'S DISEASE, SCHIZOPHRENIA, ATTENTION-DEFICIT HYPERACTIVITY, SUBSTANCE ABUSE, PHYSIOLOGICAL FUNCTION | PURDUE RESEARCH FOUNDATION | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050232870-A1 | Method of treatment of dopamine-related dysfunction | DRD2, DRD1, DRD3 | HTR2A 43/4885CYP3A4 694/4885MEN1 3521/4885 |
| US-20050080266-A1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | DRD2, COMT, CHRM3 | HTR2A 22/4885CYP3A4 210/4885MEN1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.